YD Bio Ltd
YDESHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeYD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. With a market capitalization of $350.6M, it sits in small-cap territory. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Market Cap
$350.6M
Beta
-0.16
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.04
EPS (Fwd)
—
ROE
—
ROA
—
Cash
$2.7M
Total Debt
$5,002
Free CF
—
52W Change
-71.1%
Annual Financials
Cash vs Debt
Where YDES stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, YDES finished 45.87% above its 150-day moving average ($4.36) and 7.80% above its 200-day moving average ($5.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is YDES overbought or oversold?
At the October 15, 2026 close, YDES's RSI(14) was 60.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
YD Bio Ltd holds $2.7M in cash against $5K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Revenue has grown from $350K (2023) to $597K (2025), reflecting a 70% increase over the period.
The relatively low beta of -0.16 suggests YDES is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, YDES has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing YDES's risk profile alongside its fundamentals and technical indicators provides a more complete picture.